Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Theratechnologies (TH.TO)

Theratechnologies (TH.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Theratechnologies Provides Update on EGRIFTA SV® Supply

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Resumed Production of EGRIFTA SV®

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

HDL : 23.29 (+1.84%)
TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)

Barchart Exclusives

Crude Oil: The Reality of "Drill, Baby, Drill" for the 2025 Driving Season
President Trump has been drumming, "Drill, Baby, Drill!" He will most likely lower oil and refined product prices in time. But how long will that take? Mother nature, consumer spending, and habits dominate the upcoming driving season, and oil prices are looking to increase. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar